Cordis: Cypher stent provides sustained benefits in coronary artery disease patients

By E. Janene Geiss

Philadelphia, Sept. 6 - Cordis Corp., a Johnson & Johnson company, said Wednesday that data show the Cypher sirolimus-eluting coronary stent continues to provide long-term clinical benefits at four years compared to bare-metal stents in patients with coronary artery disease.

The E-Sirius trial is one of the longest-running European studies comparing the safety and efficacy of a drug-eluting stent to a bare-metal stent, the Miami Lakes, Fla., medical technology company said in a news release.

Target lesion revascularization, the need to re-intervene to open an artery, was reduced 73% in patients receiving the Cypher stent compared to those receiving a bare-metal stent. Major adverse cardiac events were reduced by 54% compared to patients receiving a bare-metal stent, officials said.

Late stent thrombosis or blood clots also were rare in the four years of the study.

Results of the study were presented Wednesday at the World Congress of Cardiology in Barcelona, Spain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.